Abstract: A method for reducing or substantially preventing soft tissue calcification is provided. The method includes administering at least one of a downregulator of at least one plasmin inhibitors and plasmin(ogen) to a subject in need thereof, wherein the at least one plasmin inhibitor includes alpha2-antiplasmin. Further disclosed is a method comprises administering the compound subsequent to muscle injury, and the method further comprising administering an antifibrinolytic.

Abstract: The invention provides methods for evaluating the therapeutic benefit of a combination therapy useful for treating a medical disorder, such as cancer.

Abstract: A wearable device operably worn by a user for monitoring musculoskeletal loading on structure inside the body of the user includes a plurality of sensors, each sensor operably worn by the user at a predetermined location and configured to detect information about a biomechanical activity of musculoskeletal tissues, a limb segment orientation, and/or a loading magnitude or location thereon; and a processing unit in communication with the plurality of sensors and configured to process the detected information by the plurality of sensors to estimate the musculoskeletal loading, and communicate the estimated musculoskeletal loading to the user and/or a party of interest.

Abstract: Disclosed is a compound of formula (I): in which all symbols are defined in the description. Also disclosed are pharmaceutical compositions including the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.

Abstract: Disclosed is a compound of formula (I): in which all symbols are defined in the description. Also disclosed are pharmaceutical compositions including the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to prevent and/or treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.

Abstract: Isoquinolinone compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.

Abstract: The disclosure provides adenosine deaminases that are capable of deaminating adenosine in DNA to treat Hutchin-son-Gilford progeria syndrome (HOPS). The disclosure also provides fusion proteins, guide RNAs and compositions comprising a Cas9 (e.g., a Cas9 nickase) domain and adenosine deaminases that deaminate adenosine in DNA, for example in a LNA gene. In some embodiments, adenosine deaminases provided herein are used to correct a C1824T mutation in LMNA. In some embodiments, the methods and compositions provided herein are used to treat Hutchinson-Gilford progeria syndrome (HGPS).

Abstract: The present disclosure is directed to antibodies binding to and inhibiting S. aureus and methods for use thereof.

Abstract: Systems and methods are provided for performing model-based cochlear implant programming (MOCIP) on a living subject with a cochlear implant (CI) to determine stimulation settings of a patient-customized electro-neural interface (ENI) model. The method includes: localizing an electrode array of the CI and intracochlear structures of the living subject to determine patient-specific electrode positions of the CI and a patient-specific anatomy shape; generating a CI electric field model based on the patient-specific electrodes positions of the CI and the patient-specific anatomy shape; and establishing an auditory nerve fiber (ANF) bundle model using the CI electric field model, and estimating neural health of the living subject using the ANF bundle model applications of the same.

Abstract: Wearable assistance devices and methods of operating the same are provided. A wearable assistance device includes an upper-body interface with a front side and a rear side and a lower-body interface with a front side and a rear side. The assistance device also includes one or more elastic members, each of the elastic members mechanically coupling the upper-body interface to the lower-body interface and extending from the rear side of the upper-body interface to the rear side of the lower-body interface and along a back of the user so as to provide an assistive force parallel to the back of the user. Further, the assistance device also includes a clutch mechanism associated with each one of the elastic members, the clutch mechanism configured for selectively adjusting the assistive force provided by the one of the elastic members.

Abstract: An apparatus for supporting a medical device on a patient includes a mounting structure configured to be fitted onto the patient to encircle at least a portion of a body part of the patient. The mounting structure includes an inner layer and an outer layer that define a confinement. A jamming material is contained within the confinement. The jamming material is configured to flow within the confinement to conform to the shape of the body part of the patient onto which the mounting structure is fitted. The mass of jamming material is configured to harden and become rigid in its conformed shape in response to a vacuum being formed in the confinement.

Abstract: The present disclosure is directed to engineered nanoparticles/liposomes that inhibit enveloped viruses and methods for use thereof.

Abstract: Provided arm biocompatible polymer compositions, and methods of printing such polymer compositions using a fused deposition modelling printer to form a solid scaffold. In particular, the disclosed compositions may include a thermoresponsive polymer, and the printed scaffold may be used as a sacrificial template providing a three-dimensional vascular structure upon temperature-dependent disintegration. The present compositions and methods may be particularly useful for engineering thick tissues.

Abstract: The present disclosure relates to genetically modified arthropods, genetically modified bacteria, and methods for controlling and/or reducing arthropod populations.

Abstract: The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

Abstract: A system for transcranial magnetic resonance (MR)-guided focused ultrasound and method of using transcranial MR-guided focused ultrasound are disclosed. The system includes a transcranial ultrasound transducer configured to apply ultrasound radiation to a patient's head. The system also includes an antenna that reflects radio frequency (RF) waves. The antenna is configured to be positioned between the transducer and the patient's head. The antenna and at least a portion of the patient's head are surrounded by a fluid. Embodiments foster improved MR image quality scans of the patient's head when the transducer is filled with the fluid.

Abstract: Hemofilters for in vivo filtration of blood are disclosed. The hemofilters disclosed herein provide an optimal flow of blood through the filtration channels while maintaining a pressure gradient across the filtration channel walls to enhance filtration and minimize turbulence and stagnation of blood in the hemofilter.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing Japanese Encephalitis virus and methods for use thereof.

Abstract: A nucleic acid molecule is uniquely designed and encodes an entire CRISPRi or CRISPRa system, while being sized for packaging within a single adeno-associated virus (AAV) vector. Examples of the nucleic acid molecule include about 4600 to 4700 base pairs. Examples of the nucleic acid molecule can include a nucleotide encoding a Cas polypeptide; a nucleotide encoding a repressor or an activator domain attached to the nucleotide encoding the Cas polypeptide via a linker; a first promoter operably connected to the nucleotide encoding the repressor or activator domain or the nucleotide encoding the Cas polypeptide; a nucleotide encoding an alpha-helical connecting the nucleotide encoding the Cas polypeptide to a nuclear localization signal (NLS); and a second promoter operably connected to a guide RNA (gRNA).

Abstract: The present invention relates to compositions and methods for preventing and reducing inflammation and preventing and treating diseases and disorders associated with inflammation. It has been shown that CRADD plays a pivotal role in maintaining the integrity of endothelial monolayers. The recombinant cell-penetrating CRADD protein (CP-CRADD)-based compositions and methods described herein provide for the development of a novel treatment for inflammatory vascular disorders including cardiovascular, cerebrovascular, respiratory, gastrointestinal, and renal systems.